Health Condition 1: C509- Malignant neoplasm of breast of unspecified site
Conditions
Interventions
Intervention1: Nil: Nil
Intervention2: Nil: Nil
Intervention3: Nil: Nil
Sponsors
Pranav Gopal Jawade
Eligibility
Inclusion criteria
Inclusion criteria: Age above 18 years and both genders. Histologically diagnosed metastatic and non-metastatic carcinoma planned for Anthracycline- based Chemotherapy, Immunotherapy & HER 2 NEU targeted therapy.
Exclusion criteria
Exclusion criteria: Any previous existing LV dysfunction. Any pre-existing ischemic heart disease, Arrhythmias, and congenital heart disease. Any history of previously treated or ongoing treatment of heart failure. Gross derangement in any metabolic parameters that can affect GLS, like sepsis and anemia.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Primary outcome To determine the H FABP as a cardiac biomarker in predicting cardiac dysfunction among cancer patients associated with Anthracycline chemotherapy, Immunotherapy and HER 2 NEU targeted therapy Secondary Outcome To Find co-relation between H FABP and other cardiac biomarkers like Trop T and NT-pro BNP with GLS AVG to detect the cardiac toxicity associated with Anthracycline chemotherapy, Immunotherapy and HER 2 NEU targeted therapyTimepoint: Baseline, 3rd month and 6th month | — |
Secondary
| Measure | Time frame |
|---|---|
| NILTimepoint: NIL | — |
Countries
India
Contacts
Public ContactPranav Gopal Jawade
Kasturba Medical College and Hospital
Outcome results
None listed